Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CORT Corcept Therapeutics

Pre-Mkt 07-14 05:36:05 EDT

85.90

-5.98

-6.51%

High91.49	Low84.88	Vol1.33M
Open90.30	D1 Closing91.88	Amplitude7.19%
Mkt Cap9.22B	Tradable Cap7.73B	Total Shares107.36M
T/O115.33M	T/O Rate1.47%	Tradable Shares89.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CORT","market":"US","secType":"STK","nameCN":"Corcept Therapeutics","latestPrice":85.9,"timestamp":1783972800000,"preClose":91.88,"halted":0,"volume":1325305,"delay":0,"changeRate":-0.0650848933391379,"floatShares":89941100,"shares":107356686,"eps":0.35,"marketStatus":"Pre-Mkt","change":-5.98,"latestTime":"07-14 05:36:05 EDT","open":90.3,"high":91.49,"low":84.88,"amount":115327338.68834999,"amplitude":0.071942,"askPrice":90.92,"askSize":48,"bidPrice":84.18,"bidSize":36,"shortable":3,"etf":0,"ttmEps":0.35,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1784035800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1081915200000,"exchange":"NASDAQ","adjPreClose":85.9,"postHourTrading":{"tag":"盘后","latestPrice":84.7433,"preClose":85.9,"latestTime":"19:59 EDT","volume":79983,"amount":6870156.3275,"timestamp":1783987151829,"change":-1.1567,"changeRate":-0.013466,"amplitude":0.013466},"volumeRatio":1.1689155542077456,"impliedVol":0.6823,"impliedVolPercentile":0.74},"requestUrl":"/m/hq/s/CORT/tweets","defaultTab":"tweets","newsList":[{"id":"2650976961","title":"Is Corcept Therapeutics (CORT) Fully Valued On Its Russell Index Removal?","url":"https://stock-news.laohu8.com/highlight/detail?id=2650976961","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650976961?lang=en_us&edition=fundamental","pubTime":"2026-07-10 00:32","pubTimestamp":1783614761,"startTime":"0","endTime":"0","summary":"What Corcept’s Index Removal Could Mean for Investors\nCorcept Therapeutics (CORT) was recently removed from the Russell 1000 Growth Defensive Index and the Russell 1000 Defensive Index, a shift that can influence trading activity as index funds rebalance positions.\nFor you as an investor, these index changes are less about Corcept Therapeutics business operations and more about how institutional owners that track these benchmarks may adjust their holdings. Such rebalancing can affect short...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-fully-valued-on-its-russell-ind","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-fully-valued-on-its-russell-ind","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PSCH","BK4007","CORT","BK4532","LU0566484027.USD","LU1559883803.SGD","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650914871","title":"Corcept Chief Development Officer William Guyer Disposes of USD 1.87 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2650914871","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650914871?lang=en_us&edition=fundamental","pubTime":"2026-07-09 07:55","pubTimestamp":1783554932,"startTime":"0","endTime":"0","summary":"Corcept Chief Development Officer William Guyer disposes of USD 1.87 million in common sharesCorcept: Chief Development Officer William Guyer exercised options for 20,000 common shares at USD 21.65 on","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL7XHH1p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Chief Development Officer William Guyer Disposes of USD 1.87 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","PSCH","LU0566484027.USD","FBT","LU1559883803.SGD","CORT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649711546","title":"Corcept Endocrinology President Sean Maduck Sells USD 2.19 Million of Corcept Therapeutics Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2649711546","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649711546?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:45","pubTimestamp":1783370708,"startTime":"0","endTime":"0","summary":"Corcept Endocrinology President Sean Maduck sells USD 2.19 million of Corcept Therapeutics sharesSean Maduck, President, Corcept Endocrinology at Corcept Therapeutics, reported option exercise and share sales dated July 1, 2026.Exercised stock options for 25,000 shares at USD 8.27.Sold 24,?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDLZG90m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Endocrinology President Sean Maduck Sells USD 2.19 Million of Corcept Therapeutics Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","FBT","LU0566484027.USD","CORT","LU1559883803.SGD","BK4532","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649613232","title":"Does Corcept’s Exit From Russell Defensive Indexes Reframe Its Risk Profile And Investor Base (CORT)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2649613232","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649613232?lang=en_us&edition=fundamental","pubTime":"2026-07-05 19:30","pubTimestamp":1783251030,"startTime":"0","endTime":"0","summary":"In late June 2026, Corcept Therapeutics was removed from both the Russell 1000 Defensive Index and the Russell 1000 Growth-Defensive Index, ending its inclusion in these benchmark portfolios. \nThis index removal can influence how quantitatively driven and index-tracking investors view Corcept, potentially shifting demand for the stock as portfolios are rebalanced. \nNext, we’ll examine how Corcept’s removal from key Russell defensive indexes interacts with its existing investment narrative...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/does-corcepts-exit-from-russell-defensive-indexes-reframe-it","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/does-corcepts-exit-from-russell-defensive-indexes-reframe-it","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4532","LU1559883803.SGD","FBT","LU0566484027.USD","BK4007","CORT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648681416","title":"Is Corcept Therapeutics (CORT) Undervalued On Its Russell Index Removal?","url":"https://stock-news.laohu8.com/highlight/detail?id=2648681416","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648681416?lang=en_us&edition=fundamental","pubTime":"2026-07-02 23:37","pubTimestamp":1783006645,"startTime":"0","endTime":"0","summary":"Index removal puts Corcept Therapeutics in focus\nCorcept Therapeutics (CORT) was recently removed from both the Russell 1000 Defensive Index and the Russell 1000 Growth-Defensive Index, an adjustment that can prompt trading shifts by index-tracking funds.\nFor existing and prospective shareholders, the move raises practical questions about how index-related flows might interact with Corcept Therapeutics’ current valuation, trading liquidity, and the company’s broader profile in the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-undervalued-on-its-russell-inde","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/is-corcept-therapeutics-cort-undervalued-on-its-russell-inde","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CORT","BK4007","DCF","BK4532","LU1559883803.SGD","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644030679","title":"Corcept Therapeutics Rocked by Major Insider Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2644030679","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644030679?lang=en_us&edition=fundamental","pubTime":"2026-06-19 10:03","pubTimestamp":1781834587,"startTime":"0","endTime":"0","summary":"New insider activity at Corcept Therapeutics ( ($CORT) ) has taken place on June 18, 2026. Director David L. Mahoney of Corcept Therapeutics has so...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/corcept-therapeutics-rocked-by-major-insider-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/corcept-therapeutics-rocked-by-major-insider-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","LU1559883803.SGD","LU0566484027.USD","BK4007","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644360150","title":"Corcept director David Mahoney disposes of 20,000 shares worth $1.69 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644360150","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644360150?lang=en_us&edition=fundamental","pubTime":"2026-06-19 04:31","pubTimestamp":1781814704,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics director David L. Mahoney disclosed the sale of 20,000 common shares on June 17, 2026.Shares were sold at a weighted average price of USD 84.53, held indirectly through The Black Dog Private Foundation.The foundation’s post-transaction stake was 26,147 shares.Mahoney also reported 1,237,145 shares held indirectly through the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the informatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL6YF1J2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept director David Mahoney disposes of 20,000 shares worth $1.69 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CORT","BK4532","LU1559883803.SGD","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644727456","title":"Corcept Therapeutics (CORT) Stock After 114% YTD Surge Is The Rally Justified","url":"https://stock-news.laohu8.com/highlight/detail?id=2644727456","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644727456?lang=en_us&edition=fundamental","pubTime":"2026-06-18 06:30","pubTimestamp":1781735405,"startTime":"0","endTime":"0","summary":"If you are wondering whether Corcept Therapeutics stock is still attractively priced after a strong run, the key question now is how its current share price compares with a reasonable view of fair value.\nThe stock last closed at US$81.75, with returns of 4.6% over the past week, 48.3% over the past month, 114.0% year to date, 14.8% over the past year, 264.0% over three years, and 267.3% over five years. These figures naturally raise questions about how much of the story might already be...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-stock-after-114-ytd-surge-is-the-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-stock-after-114-ytd-surge-is-the-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1559883803.SGD","BK4532","CORT","BK4211","BK4007","DCF","FCF","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644216797","title":"Corcept CFO Atabak Mokari sells common shares worth $3.22 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644216797","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644216797?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:31","pubTimestamp":1781728271,"startTime":"0","endTime":"0","summary":"Corcept CFO Atabak Mokari exercised options for 40,000 common shares at USD 19.26 on June 15, 2026.Sold 39,999 common shares the same day at weighted-average prices of about USD 80.02 to USD 82.45.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL7W40x0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Corcept CFO Atabak Mokari sells common shares worth $3.22 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT","LU1559883803.SGD","LU0566484027.USD","BK4532","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644786721","title":"Corcept Therapeutics resubmits NDA for Relacorilant in Cushing’s Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2644786721","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644786721?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:30","pubTimestamp":1781728211,"startTime":"0","endTime":"0","summary":"The company states: “Corcept Therapeutics (CORT) announced it has resubmitted its New Drug Application to the U.S. Food and Drug Administration for...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-resubmits-nda-for-relacorilant-in-cushings-syndrome-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-resubmits-nda-for-relacorilant-in-cushings-syndrome-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","CORT","BK4007","LU0566484027.USD","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644302721","title":"Corcept resubmits FDA NDA for relacorilant in Cushing’s syndrome, expects six-month review","url":"https://stock-news.laohu8.com/highlight/detail?id=2644302721","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644302721?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:28","pubTimestamp":1781728093,"startTime":"0","endTime":"0","summary":"Corcept resubmitted its NDA to the FDA for relacorilant to treat Cushing’s syndrome.The filing includes additional analyses requested by the FDA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire  on June 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL8Pyd6c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1559883803.SGD","LU0566484027.USD","BK4007","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644721379","title":"Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients With Cushing’s Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2644721379","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644721379?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:28","pubTimestamp":1781728080,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUA48KGCG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CORT","BK4532","LU0566484027.USD","LU1559883803.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644721306","title":"Corcept Therapeutics - Resubmission Includes Additional Analyses; Expects Six-Month FDA Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2644721306","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644721306?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:28","pubTimestamp":1781728080,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUA48KGCG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4532","CORT","LU0566484027.USD","BK4007","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642571411","title":"Corcept Therapeutics (CORT) Valuation After New Korlym CATALYST And MOMENTUM Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2642571411","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642571411?lang=en_us&edition=fundamental","pubTime":"2026-06-10 09:25","pubTimestamp":1781054729,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) is back in focus after presenting new CATALYST and MOMENTUM trial data at the American Diabetes Association meetings, highlighting how Korlym might affect difficult-to-control diabetes and resistant hypertension.\nSee our latest analysis for Corcept Therapeutics.\nCorcept’s recent news has added to an already strong run, with a 30 day share price return of 48.22% and a 90 day share price return of 129.67%. The 5 year total shareholder return of 253.35% points to...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-valuation-after-new-korlym-catalys","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-valuation-after-new-korlym-catalys","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4532","CORT","BK4007","LU0566484027.USD","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641331171","title":"Corcept announces presentation of new data from Catalyst, Momentum trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2641331171","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641331171?lang=en_us&edition=fundamental","pubTime":"2026-06-08 06:05","pubTimestamp":1780869906,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) announced the presentation of new data from its Catalyst and Momentum trials at the American Diabetes Association’s 86t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-announces-presentation-of-new-data-from-catalyst-momentum-trials-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-announces-presentation-of-new-data-from-catalyst-momentum-trials-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","LU0566484027.USD","LU1559883803.SGD","CORT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641178481","title":"Lifyorli Survival Data and DOJ Update Might Change The Case For Investing In Corcept Therapeutics (CORT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641178481","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641178481?lang=en_us&edition=fundamental","pubTime":"2026-06-07 09:17","pubTimestamp":1780795079,"startTime":"0","endTime":"0","summary":"In late May and early June 2026, Corcept Therapeutics reported strong overall survival data for newly approved ovarian cancer drug Lifyorli from its Phase 3 ROSELLA trial at ASCO, while also disclosing that the U.S. Department of Justice declined to intervene in a long-running qui tam lawsuit related to Korlym’s promotion and reimbursement.\nBeyond reinforcing Lifyorli’s clinical profile and guideline inclusion, these updates highlight Corcept’s evolution from a single-product Cushing’s...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/lifyorli-survival-data-and-doj-update-might-change-the-case","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/lifyorli-survival-data-and-doj-update-might-change-the-case","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CORT","AIYY","BK4588","BK4551","BK4023","BK4587","CHAT","AIPO","AI","BK4585","BK4532","LU0566484027.USD","BK4007","LU1559883803.SGD","BK4543","ARTY","BK4528","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641914167","title":"Corcept Chief Development Officer William Guyer disposes of 20,000 common shares for $1.41 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2641914167","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641914167?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:50","pubTimestamp":1780606202,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics Chief Development Officer William Guyer exercised options for 20,000 common shares at $21.65 on June 2, 2026.Guyer sold 20,000 common shares the same day at a weighted average $70.6, leaving 3,985 shares beneficially owned.The sale was executed under a Rule 10b5-1 trading plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL1NbYv9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Chief Development Officer William Guyer disposes of 20,000 common shares for $1.41 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT","BK4532","LU1559883803.SGD","LU0566484027.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640808801","title":"Corcept Endocrinology President Sean Maduck disposes of Corcept Therapeutics shares worth $1.75 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2640808801","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640808801?lang=en_us&edition=fundamental","pubTime":"2026-06-04 07:21","pubTimestamp":1780528894,"startTime":"0","endTime":"0","summary":"Sean Maduck, President, Corcept Endocrinology, reported June 1 transactions in Corcept Therapeutics common stock.Exercised stock options for 25,000 shares at USD 8.27.Sold 25,000 shares at weighted-average prices of USD 70.11 and USD 70.75.Acquired 1,230 shares at USD 70.44 and received 615 restricted shares.Withheld 452 shares at USD 70.44 for tax obligations; direct holdings ended at 9,755 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL18NRJG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Endocrinology President Sean Maduck disposes of Corcept Therapeutics shares worth $1.75 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4007","LU0566484027.USD","CORT","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640180838","title":"Corcept CFO Atabak Mokari sells 40,000 shares for USD 2.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2640180838","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640180838?lang=en_us&edition=fundamental","pubTime":"2026-06-04 07:21","pubTimestamp":1780528866,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics CFO Atabak Mokari sold 40,000 common shares on June 1 at a weighted average USD 70.He exercised stock options for 40,000 shares the same day at USD 19.26.He also acquired 1,268 shares on June 1, including 634 purchased at USD 70.44.395 shares were withheld on June 2 to cover tax obligations tied to equity vesting.He reported 16,130 common shares owned following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL6hTSNj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","CORT","LU0566484027.USD","BK4007","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640964901","title":"Corcept Therapeutics - DOJ, California Department of Insurance, and Plaintiff States Decline to Intervene in Lawsuit - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2640964901","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640964901?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:04","pubTimestamp":1780488280,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nFWN42B0A0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","CORT","BK4532","LU1559883803.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corcept.com","stockEarnings":[{"period":"1week","weight":-0.0623},{"period":"1month","weight":0.0361},{"period":"3month","weight":0.9666},{"period":"6month","weight":1.3191},{"period":"1year","weight":0.195},{"period":"ytd","weight":1.4684}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0788},{"period":"6month","weight":0.0852},{"period":"1year","weight":0.2013},{"period":"ytd","weight":0.0986}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.022337},{"month":2,"riseRate":0.409091,"avgChangeRate":0.008661},{"month":3,"riseRate":0.772727,"avgChangeRate":0.140734},{"month":4,"riseRate":0.545455,"avgChangeRate":0.005665},{"month":5,"riseRate":0.521739,"avgChangeRate":0.028192},{"month":6,"riseRate":0.478261,"avgChangeRate":0.048323},{"month":7,"riseRate":0.434783,"avgChangeRate":-0.006771},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.006283},{"month":9,"riseRate":0.454545,"avgChangeRate":0.062175},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005789},{"month":11,"riseRate":0.5,"avgChangeRate":0.018834},{"month":12,"riseRate":0.409091,"avgChangeRate":0.027449}],"exchange":"NASDAQ","name":"Corcept Therapeutics","nameEN":"Corcept Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corcept Therapeutics,CORT,Corcept Therapeutics股票,Corcept Therapeutics股票老虎,Corcept Therapeutics股票老虎国际,Corcept Therapeutics行情,Corcept Therapeutics股票行情,Corcept Therapeutics股价,Corcept Therapeutics股市,Corcept Therapeutics股票价格,Corcept Therapeutics股票交易,Corcept Therapeutics股票购买,Corcept Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction